1. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane
- Author
-
Carolyn C. Snider, Roger C. Carroll, Venkata R. Aligeti, Dale C. Wortham, and Robert M. Craft
- Subjects
Adult ,Blood Platelets ,Male ,medicine.medical_specialty ,Platelet Aggregation ,Platelet Function Tests ,Thromboxane ,Urinary system ,Point-of-Care Systems ,Drug Resistance ,Drug resistance ,Gastroenterology ,Risk Assessment ,Internal medicine ,medicine ,Humans ,Platelet ,Myocardial infarction ,Platelet activation ,Aged ,Aged, 80 and over ,Aspirin ,Risk Management ,business.industry ,Middle Aged ,medicine.disease ,Clopidogrel ,Thrombelastography ,Thromboxane B2 ,Anesthesiology and Pain Medicine ,Biological Assay ,Female ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
BACKGROUND Aspirin-resistant platelet activation in whole blood is attributable to a transcellular pathway not detected by isolated platelet aggregometry. Aspirin resistance as defined by urinary thromboxane levels is associated with increased risk for myocardial infarction or cardiac death. Whole blood point-of-care assays may also detect aspirin resistance. METHODS We compared PlateletMapping® with VerifyNow® for detecting aspirin resistance in 200 patients undergoing invasive cardiac procedures. This included 10 patients not receiving aspirin therapy for comparison. The assay results were correlated with urinary 11-dehydro-thromboxane B2 collected 2 to 8 hours after the procedure. RESULTS PlateletMapping detected aspirin resistance in 32% of patients. VerifyNow detected aspirin resistance in 6% of patients. A patient's compliance with aspirin therapy was confirmed by a
- Published
- 2013